B. Riley reaffirmed their buy rating on shares of Viking Therapeutics (NASDAQ:VKTX) in a research report report published on Thursday morning, TipRanks reports. B. Riley currently has a $12.00 target price on the biotechnology company’s stock.
Other equities analysts have also issued research reports about the stock. BTIG Research initiated coverage on shares of Viking Therapeutics in a research report on Friday, May 1st. They set a buy rating and a $9.00 target price for the company. Chardan Capital reissued a buy rating and issued a $15.00 price target on shares of Viking Therapeutics in a report on Wednesday. BidaskClub downgraded shares of Viking Therapeutics from a hold rating to a sell rating in a report on Wednesday, July 15th. William Blair reissued a buy rating on shares of Viking Therapeutics in a report on Friday, April 3rd. Finally, BMO Capital Markets initiated coverage on shares of Viking Therapeutics in a report on Thursday, June 4th. They issued an outperform rating and a $14.00 price target on the stock. One research analyst has rated the stock with a sell rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. The company presently has a consensus rating of Buy and an average target price of $14.78.
Shares of NASDAQ:VKTX opened at $7.02 on Thursday. Viking Therapeutics has a twelve month low of $3.26 and a twelve month high of $8.87. The company has a 50-day moving average price of $7.11 and a two-hundred day moving average price of $6.41.
Viking Therapeutics (NASDAQ:VKTX) last issued its earnings results on Wednesday, July 29th. The biotechnology company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.01. Analysts predict that Viking Therapeutics will post -0.6 EPS for the current fiscal year.
In related news, Director Matthew W. Foehr sold 13,000 shares of the firm’s stock in a transaction that occurred on Tuesday, June 30th. The shares were sold at an average price of $7.35, for a total value of $95,550.00. Following the sale, the director now directly owns 26,250 shares of the company’s stock, valued at $192,937.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 3.70% of the company’s stock.
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Cornerstone Investment Partners LLC purchased a new stake in Viking Therapeutics in the second quarter valued at approximately $129,000. Brinker Capital Inc. raised its stake in Viking Therapeutics by 6.1% in the second quarter. Brinker Capital Inc. now owns 31,712 shares of the biotechnology company’s stock valued at $229,000 after purchasing an additional 1,811 shares in the last quarter. Raymond James & Associates raised its stake in shares of Viking Therapeutics by 46.7% during the second quarter. Raymond James & Associates now owns 380,044 shares of the biotechnology company’s stock worth $2,740,000 after acquiring an additional 120,986 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Viking Therapeutics by 106.9% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,149 shares of the biotechnology company’s stock worth $59,000 after acquiring an additional 4,210 shares in the last quarter. Finally, XTX Markets LLC purchased a new position in shares of Viking Therapeutics during the second quarter worth approximately $111,000. 54.21% of the stock is currently owned by institutional investors and hedge funds.
Viking Therapeutics Company Profile
Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in Phase 2b clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis.
Featured Article: What is a death cross?
Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.